CNS Pharmaceuticals Inc (NASDAQ: CNSP) gave its clinical and operational progress on Berubicin in a video presentation to its shareholders. According to the company’s CEO, John Climaco, CNS Pharmaceuticals employees are conscious of the relationship between the company operations and share value. Climaco, a shareholder, states that he understands other shareholders’ issues with share fluctuation due to the current market conditions.
The company is testing the safety and efficacy of the therapy
However, Climaco points out that these changes are not in the company’s control. Climaco can control CNS Pharmaceuticals’ operations and has ensured that the company is on the right path. The company is recruiting volunteers globally to test for the efficacy and safety of Berubicin to treat adult glioblastoma multiforme (GBM).
Moreover, the company has employed top specialists worldwide to take charge of the project. It also maintains a dialog with the Food and Drug Administration (FDA) so that its trial matches up with the proper technology.
While the company has no control of market conditions, it is doing its best to ensure its leading drug Berubicin can become a preferred treatment for patients worldwide. Climaco adds that the therapy could be a game-changer for people with GBM.
Berubicin is an anthracycline that crosses the blood-brain barrier. This fact is crucial as no other anthracycline does this. For this reason, the company is trying to use the drug to treat central nervous system (CNS) and brain oncology conditions.
The company’s projects
CNS Pharmaceuticals is currently conducting doing randomizations and enrollment. Furthermore, it has many clinical sites worldwide to enhance enrolment and activation.
CNS Pharmaceuticals is a company focused on developing drugs for metastasizing and primary CNS and brain cancers such as glioblastoma multiforme, which is incurable and aggressive.
It is also improving on the WP1244/WP1874 technology. This drug technology used distamycin and anthracycline-based scaffolds for developing small molecules. Experts believe that this formulation is 500× stronger in preventing the proliferation of tumor cells than daunorubicin. Its uptake by the brain is also high.
The company is also investigations if they can use the drug technology to treat primary CNS and brain cancer. It is also evaluating its effects on cancers that metastasize to the CNS, such as lymphomas, ovarian, and pancreatic cancers.
